Articles related to ADDICTION MEDICINE

Semaglutide, a familiar medication for obesity and type 2 diabetes, might pave a new path in managing alcohol dependence. Unearth the potential of this medication, which could reshape our understanding of alcohol dependence treatment.

The I-WOTCH trial offers insightful findings on multimodal interventions for opioid-dependent chronic pain patients. Read on for a detailed examination of the trial’s significant impact on patient wellbeing and opioid cessation.

Opvee Reverses Remifentail-induced Respiratory Depression Within 5 Minutes As the opioid crisis continues to evolve, so too does your arsenal of interventions. The FDA’s recent approval of Opvee, a nalmefene-based nasal spray, introduces a new tool for physicians in the fight against opioid overdose.

Understanding Xylazine: The Rising Challenge in Opioid Crisis Management As physicians, it’s crucial to stay informed about emerging drug threats. Xylazine, a powerful livestock tranquilizer mixed into fentanyl, is one such threat that’s gaining momentum.

A 37-year-old man presented with persistent swelling, limited range of motion, and loss of hand dexterity in both hands. He had a history of IV drug use, including opiates and methamphetamine. The examination showed diffuse swelling without joint inflammation. Lab tests were normal, and imaging revealed soft-tissue swelling. The diagnosis was puffy hand syndrome, a common complication of IV drug use. Treatment options are mainly symptomatic, including discontinuation of IV drug use and the use of low-stretch bandages and compression gloves. Puffy hand syndrome, often unrecognized by general practitioners, should be considered in patients with swelling and limited hand function who have a history of IV drug use. The syndrome involves progressive fibrosis of subcutaneous tissues due to repeated injection-induced vascular and dermal sclerosis. Diagnosis is based on clinical presentation, history, and evaluation ruling out other conditions. Treatment focuses on symptomatic relief and cessation of IV drug use.

NEW YORK CITY | THE GLASSHOUSE CHELSEASATURDAY, JUNE 24, 2023 In a comprehensive in-person setting, psychiatrists will get current, clinically relevant, and practice-based updates. This full-day conference will feature interesting presentations conducted by renowned thought leaders in schizophrenia, postpartum depression, major depressive disorder, ADHD, and addiction. Each session will include a patient perspective to ensure professionals obtain practical, real-world understanding.